Following this activity, participants should be able to: (1) Describe the prevalence of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) in rectal cancer. (2) Illustrate the role of neoadjuvant immunotherapy for the treatment of locally advanced or metastatic rectal cancer. (3) Discuss key patient counseling and monitoring considerations for neoadjuvant immunotherapy in locally advanced setting for rectal cancer.
- Provider:National Comprehensive Cancer Network
- Activity Link: https://education.nccn.org/node/96340
- Start Date: 2024-12-20 06:00:00
- End Date: 2024-12-20 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Exelixis - Amount: 0.0 - Is Kind Support: False Source: GlaxoSmithKline - Amount: 0.0 - Is Kind Support: False Source: Menarini-Stemline - Amount: 0.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0.0 - Is Kind Support: False Source: Regeneron Pharmaceuticals, Inc. - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest